Adagio Therapeutics announced its lead monoclonal antibody has neutralization activity against the Omicron variant of SARS-CoV-2. Adagio is evaluating ADG20 in its global Phase 2/3 clinical trials for prevention and treatment of COVID-19. Adagio is engaging with the FDA regarding protocol updates to its global Phase 2/3 clinical trials. My price target is...
The chart speaks for itself: ARDS is in a massive bullish divergence at all time low levels from which can explode anytime soon! Recently, analyst Vernon Bernardino from H.C. Wainwright, who reiterated a buy rating and $19 price target on ARDS , told investors that Aridis Pharmaceuticals Inc 's monoclonal Covid-19 Antibody Cocktail is potentially First-in-Class...
first of all thanks for stopping by.. This text below will be posted on every timeframe Until now, not much was known about Novavax because it was Moderna or Pfizer what was on the news and media, but now NOVAVAX has been in the news and so that's why the chart popped up on my radar . On the big picture I'm looking at the 2 monthly chart To remove some noise and...
first of all thanks for stopping by.. This text below will be posted on every timeframe Until now, not much was known about Novavax because it was Moderna or Pfizer what was on the news and media, but now NOVAVAX has been in the news and so that's why the chart popped up on my radar . On the big picture I'm looking at the 2 monthly chart To remove some noise and...
first of all thanks for stopping by.. This text below will be posted on every timeframe Until now, not much was known about Novavax because it was Moderna or Pfizer what was on the news and media, but now NOVAVAX has been in the news and so that's why the chart popped up on my radar . On the big picture I'm looking at the 2 monthly chart To remove some noise and...
Graham Mullis, CEO of the Novacyt Group, commented: “Novacyt continues to process COVID-19 tests for current and future demand. We continue to ensure that innovation is at the center of our strategy and that our growing portfolio of COVID-19 tests is available to clients in private and public healthcare facilities to expand existing partnerships and support new...
$MRNA $308 or $300 bounce (If we get below then reclaim these levels, take a position for calls) Price targets: 308->310 300->305 Technical analysis: Bounce off pivot point around 308 area or bounce off psychological level at 300 Rationale: With increasing news of a new virus variant, vaccine stocks are rallying so there is built up potential for more momentum
Moderna, Inc., a biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases. As of March 9, 2021, the company had 13 programs in clinical trials and a total of 24 development programs in six modalities comprising...
$BNTX BioNTech got wrecked since its August high and lost over 50% of its value. BNTX is at it's 200 day moving average, if that holds as support, it is a very nice swingtrade setup. With Covid numbers rising all across the world and booster vaccines for everybody getting more and more a thing, BNTX could possibly go on another bullrun cycle. Approach with...
Today we will review Merck & Co stocks as I have promised recently. The company announced the launch of the first oral medication against COVID-19 with proven efficiency. Let’s analyse the chart with the Merck stocks and their upside potential. When doing analysis it is traditionally better to start from the eldest timeframes to distinguish the existing trend....
As one of stocks that are significantly impacted by COVID, AHT price seems to be stable at current level (even if the market went down this month). Given that the last earning report looks good to me, I would open long as soon as this market correction ends. Besides the general trend analysis, there are some technical supports: resistance level 14.00 had been...
After Pfiser's booster shot approval this month, $MRNA will surely follow. Today, they announced a combined flu and COVID shot, as well as signing a multi-year deal with a manufacturer, National Risilience Inc, which will help reach its 2021 goal of delivering 800M-1B doses of its vaccine. This has got the stock soaring and the rim of the cup is forming as you...
We can found a technical figure Triangle in Spanish company Aena, SME S. A. (AENA.mc) on a daily chart. Aena, SME S. A.is a Spanish public company incorporated as a public limited company that manages general interest airports in Spain. The company, which is 51% owned by the public business entity ENAIRE, operates 45 airports and two heliports in Spain and...
Idea for COVID-19: - We believe that the fight against COVID-19 has entered the mid game. - Can COVID-19 be beaten in the game of evolution? We think so. Viruses are rational actors, and will behave as a population in the interests of their evolutionary fitness. - While the media's narrative of "wave 3" of COVID-19 has spread and is widely known, Motive Wave 2 of...
Not financial advice but I've been working with an associate to "resurrect" his squashed grapes of a portfolio and TSOI has already doubled it's portion of the equity in that account. Without getting too deep into it, the FIbs are pretty reliable on this OTC stock so DYOR, dive in and swim!! Good luck!
Pfizer’s been a fairly boring chart to look at but it could be something you might want to keep your eyes on since it’s finally broken above its all time highs. It’s starting to look like a very nice long term trade! - Factor Four
Target price $10, after hitting a 52 week low, IMVT is looking good for a bounce.
DVAX retracement plotted using recent lows and the high from Aug 2018...figured that would be more than enough on the big picture to see any potential levels of interest. In this case, sure enough, there were. Mainly, the 236 fib line has been an area of higher traffic over the last 3 years. Further, DVAX has yet to establish a substantial support above this...